Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
Titel:
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
Auteur:
Motzer, Robert J Powles, Thomas Burotto, Mauricio Escudier, Bernard Bourlon, Maria T Shah, Amishi Y Suárez, Cristina Hamzaj, Alketa Porta, Camillo Hocking, Christopher M Kessler, Elizabeth R Gurney, Howard Tomita, Yoshihiko Bedke, Jens Zhang, Joshua Simsek, Burcin Scheffold, Christian Apolo, Andrea B Choueiri, Toni K